Women with PCOS consistently show reduced follistatin expression in ovarian tissue, and this deficit appears to contribute to impaired follicle development and androgen accumulation within the follicular environment.[10] The therapeutic angle is intellectually compelling
In preclinical settings, researchers study Cagrilintide to evaluate pathways that control food intake, satiety, and glycemic management, making it a promising candidate for obesity and metabolic-related research
Retatrutide also improved insulin sensitivity and glucose metabolism beyond what youd expect from weight loss alone, suggesting direct receptor-mediated effects on metabolic tissues
Body composition, metabolic characteristics, and insulin resistance in obese and Nonobese women with polycystic ovary syndrome
All trajectories were analysed with simulation event analysis and simulation interaction diagrams of DESMOND